We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy and feasibility of ruxolitinib in chronic steroid‐refractory GVHD in a pediatric intestine transplant.
- Authors
Ghobrial, Shahira; Gonzalez, Corina; Yazigi, Nada; Kaufman, Stuart; Matsumoto, Cal; Fishbein, Thomas; Hawksworth, Jason; Kroemer, Alexander; Khan, Khalid
- Abstract
Acute graft‐versus‐host disease (GvHD) has been a clinical problem in solid organ transplant that includes intestine due to the donor lymphoid tissue mass which accompanies the intestinal component of the graft. We report a case that demonstrated the efficacy and feasibility of ruxolitinib a JAK 1/2 inhibitor in the treatment of chronic steroid‐refractory GVHD (SR‐GVHD). The child developed SR‐GVHD following a composite intestine transplant (small bowel, colon, liver, and pancreas). And after receiving ruxolitinib 1.25 mg (0.15 mg/kg/dose) per gastric tube (G‐tube) daily, the child appeared to have improved skin rash and sigmoidoscopy was negative. Nonetheless, we encourage close monitoring of hematologic and infectious adverse effect during dose escalation, and individualizing patient maximum effective dose with the least adverse effect possible. We stress the importance of early diagnosis and hyper‐alertness of GVHD in intestinal transplant patients.
- Subjects
SMALL intestine; INTESTINES; GRAFT versus host disease; TRANSPLANTATION of organs, tissues, etc.; LYMPHOID tissue; BLOOD transfusion reaction
- Publication
Pediatric Transplantation, 2021, Vol 25, Issue 3, p1
- ISSN
1397-3142
- Publication type
Article
- DOI
10.1111/petr.13836